NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Mehmet Asım Bilen(Emory Healthcare), Ahsan Rizwan(Nektar Therapeutics (United States)), Adi Diab(Cleveland Clinic), Erin E. Karski(Allogene Therapeutics (United States)), Ute Hoch(University of Arizona), Giovanni Grignani(Candiolo Cancer Institute), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Mary Tagliaferri(Nektar Therapeutics (United States)), Arjun Vasant Balar(NYU Langone Health), Mayer Fishman(Moffitt Cancer Center), Alison L. Hannah(CytomX Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 22
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k